A new consensus report on the management of type 1 diabetes in adults was presented recently at the European Association for ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

People with type 1 diabetes achieved significantly better long-term blood glucose when their levels were monitored by health ...

“Tubeless” automated insulin delivery (AID) systems lead to significant improvements in healthcare-related quality of life ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Young people with new-onset type 1 diabetes enrolled in ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found big increases in the use of continuous glucose monitoring and insulin delivery devices by children and ...

A new experimental treatment may be able to cure type 1 diabetes. About 83% of the patients were able to stop using insulin after the treatment. Research into the treatment is ongoing. Experts explain ...

Type 1 diabetes is an auto-immune condition whereby the patient’s own immune system attacks the pancreatic islets, destroying them in the process. Since these islets are responsible for producing ...

When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune system attacks and destroys the beta cells that produce ...

MIAMI, FL / ACCESS Newswire / October 9, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the development of innovative ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Vertex Pharmaceuticals’ CRISPR-based therapy made history as ...